{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:51:59Z","timestamp":1794109919253,"version":"4.8.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"Importance<\/jats:title>An accurate noninvasive biomarker test is needed for the early diagnosis of bladder cancer.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the performance of a urinary DNA methylation test (PENK<\/jats:italic> methylation) and compare its diagnostic accuracy with that of the nuclear matrix protein 22 (NMP22) test or urine cytology test.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>In this prospective multicenter study at 10 sites in the Republic of Korea, individuals 40 years and older with hematuria undergoing cystoscopy within 3 months between March 11, 2022, and May 30, 2024, participated. The study participants were evaluated for bladder cancer using a urinary DNA methylation test.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Urinary DNA methylation test, NMP22 test, and urine cytology test.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcomes were the sensitivity and specificity of the urinary DNA methylation test for high-grade or invasive bladder cancer. Secondary objectives included the accuracy of the test for overall bladder cancer (all stages and grades) and the comparison of sensitivities and specificities for bladder cancer between the urinary DNA methylation test and the NMP22 test or urine cytology test.<\/jats:p><\/jats:sec>Results<\/jats:title>Among the 1099 participants, 614 (55.9%) were male; participants had a mean (SD) age of 65 (10) years. Of the 1099 participants, 219 and 176 participants had bladder cancer and high-grade or invasive bladder cancer, respectively. The urinary DNA methylation test had sensitivity and specificity for high-grade or invasive bladder cancer of 89.2% (95% CI, 84.6%-93.8%) and 87.8% (95% CI, 85.6%-89.9%), respectively. Sensitivity and specificity for overall bladder cancer were 78.1% (95% CI, 72.6%-83.6%) and 88.8% (95% CI, 86.7%-90.8%), respectively. The positive predictive value for high-grade or invasive bladder cancer was 61.3% (95% CI, 55.4%-67.3%), and the negative predictive value was 97.6% (95% CI, 96.6%-98.7%). In comparison with the NMP22 test or urine cytology test, the urinary DNA methylation test showed significantly superior sensitivity for high-grade or invasive bladder cancer and overall bladder cancer.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this prospective multicenter study of individuals with hematuria, the urinary DNA methylation test showed 89% sensitivity for detecting high-grade or invasive bladder cancer, outperforming the NMP22 test or urine cytology test with high specificity. While this test had an excellent negative predictive value, its positive predictive value was suboptimal.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2024.6160","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T16:32:32Z","timestamp":1738254752000},"page":"293","source":"Crossref","is-referenced-by-count":31,"title":["Urinary DNA Methylation Test for Bladder Cancer Diagnosis"],"prefix":"10.1001","volume":"11","author":[{"given":"In Gab","family":"Jeong","sequence":"first","affiliation":[{"name":"Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Cheol","family":"Yun","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Koo","family":"Ha","sequence":"additional","affiliation":[{"name":"Department of Urology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Gu","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Urology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangchul","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Urology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungchan","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Hwan","family":"Sung","sequence":"additional","affiliation":[{"name":"Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Il","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Urology, Ajou University School of Medicine, Suwon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eu Chang","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Urology, Chonnam National University Medical School, Gwangju, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Cheol","family":"Moon","sequence":"additional","affiliation":[{"name":"Department of Pathology, Seoul National University Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheol","family":"Kwak","sequence":"additional","affiliation":[{"name":"Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"coi240078r1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023.","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"coi240078r2","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.euo.2022.10.003","article-title":"Epidemiology, screening, and prevention of bladder cancer.","volume":"5","author":"Lobo","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"coi240078r3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ).","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"issue":"10","key":"coi240078r4","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41585-023-00773-8","article-title":"Urine biomarkers in bladder cancer\u2014current status and future perspectives.","volume":"20","author":"Maas","year":"2023","journal-title":"Nat Rev Urol"},{"issue":"3","key":"coi240078r5","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/iju.15338","article-title":"Urinary markers for bladder cancer diagnosis: a review of current status and future challenges.","volume":"31","author":"Tomiyama","year":"2024","journal-title":"Int J Urol"},{"issue":"1","key":"coi240078r6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.urolonc.2020.08.016","article-title":"Urinary biomarkers in bladder cancer: a review of the current landscape and future directions.","volume":"39","author":"Ng","year":"2021","journal-title":"Urol Oncol"},{"issue":"20","key":"coi240078r7","doi-asserted-by":"publisher","first-page":"8169","DOI":"10.1158\/0008-5472.CAN-10-1335","article-title":"Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue.","volume":"70","author":"Wolff","year":"2010","journal-title":"Cancer Res"},{"issue":"12","key":"coi240078r8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s11934-018-0861-5","article-title":"Epigenetic alterations in bladder cancer.","volume":"19","author":"Porten","year":"2018","journal-title":"Curr Urol Rep"},{"issue":"7","key":"coi240078r9","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1158\/1055-9965.EPI-11-0067","article-title":"Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments.","volume":"20","author":"Chung","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"coi240078r10","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1186\/s12885-022-10275-2","article-title":"Identification and validation of methylated PENK gene for early detection of bladder cancer using urine DNA.","volume":"22","author":"Oh","year":"2022","journal-title":"BMC Cancer"},{"issue":"7","key":"coi240078r11","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jmoldx.2024.04.001","article-title":"EarlyTect BCD, a streamlined PENK methylation test in urine DNA, Effectively detects bladder cancer in patients with hematuria.","volume":"26","author":"Bang","year":"2024","journal-title":"J Mol Diagn"},{"issue":"9","key":"coi240078r12","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jmoldx.2023.05.003","article-title":"Evaluation of sensitive urine DNA-based PENK methylation test for detecting bladder cancer in patients with hematuria.","volume":"25","author":"Oh","year":"2023","journal-title":"J Mol Diagn"},{"issue":"1","key":"coi240078r13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0022-5347(05)67972-4","article-title":"Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome.","volume":"163","author":"Herr","year":"2000","journal-title":"J Urol"},{"issue":"6","key":"coi240078r14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.urology.2005.07.063","article-title":"Low-grade Ta (noninvasive) urothelial carcinoma of the bladder.","volume":"66","author":"Oosterlinck","year":"2005","journal-title":"Urology"},{"issue":"4","key":"coi240078r15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/bju.14995","article-title":"Risk-adapted management of low-grade bladder tumours: recommendations from the International Bladder Cancer Group (IBCG).","volume":"125","author":"Matulay","year":"2020","journal-title":"BJU Int"},{"issue":"4","key":"coi240078r16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/his.14764","article-title":"What\u2019s new in WHO fifth edition\u2014urinary tract.","volume":"81","author":"Comperat","year":"2022","journal-title":"Histopathology"},{"issue":"4","key":"coi240078r17","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.eururo.2017.12.018","article-title":"Updates in the eighth edition of the Tumor-Node-Metastasis Staging classification for urologic cancers.","volume":"73","author":"Paner","year":"2018","journal-title":"Eur Urol"},{"issue":"5","key":"coi240078r18","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.eururo.2014.10.040","article-title":"Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review.","volume":"67","author":"Casey","year":"2015","journal-title":"Eur Urol"},{"issue":"3","key":"coi240078r19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jasc.2016.04.005","article-title":"The Paris System for Reporting Urinary Cytology: the quest to develop a standardized terminology.","volume":"5","author":"Barkan","year":"2016","journal-title":"J Am Soc Cytopathol"},{"issue":"6","key":"coi240078r20","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0272989X06295361","article-title":"Decision curve analysis: a novel method for evaluating prediction models.","volume":"26","author":"Vickers","year":"2006","journal-title":"Med Decis Making"},{"issue":"9","key":"coi240078r21","first-page":"882","article-title":"Accuracy of grading of urothelial carcinoma on urine cytology: an analysis of interobserver and intraobserver agreement.","volume":"5","author":"Reid","year":"2012","journal-title":"Int J Clin Exp Pathol"},{"issue":"1","key":"coi240078r22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","article-title":"Bladder cancer.","volume":"9","author":"Dyrskj\u00f8t","year":"2023","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"coi240078r23","doi-asserted-by":"publisher","first-page":"922","DOI":"10.7326\/M15-0997","article-title":"Urinary biomarkers for diagnosis of bladder cancer: a systematic review and meta-analysis.","volume":"163","author":"Chou","year":"2015","journal-title":"Ann Intern Med"},{"issue":"2","key":"coi240078r24","doi-asserted-by":"publisher","first-page":"66.e25","DOI":"10.1016\/j.urolonc.2014.06.008","article-title":"Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer.","volume":"33","author":"Yafi","year":"2015","journal-title":"Urol Oncol"},{"issue":"3","key":"coi240078r25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.3050","article-title":"Management, surveillance patterns, and costs associated with low-grade papillary stage Ta non-muscle-invasive bladder cancer among older adults, 2004-2013.","volume":"5","author":"Bree","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"4","key":"coi240078r26","first-page":"412","article-title":"Urine cytology and adjunct markers for detection and surveillance of bladder cancer.","volume":"2","author":"Sullivan","year":"2010","journal-title":"Am J Transl Res"},{"issue":"1","key":"coi240078r27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0022-5347(05)66080-6","article-title":"Screening and monitoring for bladder cancer: refining the use of NMP22.","volume":"166","author":"Ponsky","year":"2001","journal-title":"J Urol"},{"issue":"6","key":"coi240078r28","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41576-022-00465-w","article-title":"DNA methylation-based predictors of health: applications and statistical considerations.","volume":"23","author":"Yousefi","year":"2022","journal-title":"Nat Rev Genet"},{"issue":"3","key":"coi240078r29","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.juro.2015.08.085","article-title":"Evaluation of an epigenetic profile for the detection of bladder cancer in patients with hematuria.","volume":"195","author":"van Kessel","year":"2016","journal-title":"J Urol"},{"issue":"4","key":"coi240078r30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.euo.2018.06.011","article-title":"Performance of the bladder EpiCheck methylation test for patients under surveillance for non-muscle-invasive bladder cancer: results of a multicenter, prospective, blinded clinical trial.","volume":"1","author":"Witjes","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"coi240078r31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13148-016-0303-5","article-title":"UroMark\u2014a urinary biomarker assay for the detection of bladder cancer.","volume":"9","author":"Feber","year":"2017","journal-title":"Clin Epigenetics"},{"issue":"12","key":"coi240078r32","doi-asserted-by":"publisher","first-page":"6278","DOI":"10.1172\/JCI139597","article-title":"Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer.","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Invest"},{"issue":"1","key":"coi240078r33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13148-022-01335-2","article-title":"BladMetrix: a novel urine DNA methylation test with high accuracy for detection of bladder cancer in hematuria patients.","volume":"14","author":"Pharo","year":"2022","journal-title":"Clin Epigenetics"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2829522\/jamaoncology_jeong_2025_oi_240078_1741392592.80574.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T21:11:32Z","timestamp":1742505092000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2829522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.6160","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,1]]}}}